Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Hosing

Showing results (171-180 of 234) with videos related to

Pageof 24
Sort By:
Cancer|May 21, 2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphomaYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2015
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory LymphomasYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2013
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantationRohtesh S Mehta, Antonio Di Stasi, Borje S Andersson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic SyndromeGheath Alatrash, Peter F Thall, Benigno C Valdez, et al.
American Journal of Hematology|January 11, 2012
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myelomaQaiser Bashir, Hassan Khan, Robert Z Orlowski, et al.
Transplantation and Cellular Therapy|March 30, 2021
Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple MyelomaSamer A Srour, Rima M Saliba, Qaiser Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 28, 2016
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaFleur M Aung, Benjamin Lichtiger, Gabriela Rondon, et al.
Annals of Hematology|June 28, 2019
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemiaNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Pageof 24

Showing results (171-180 of 234) with videos related to

Sort By:
Pageof 24
Cancer|May 21, 2016
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphomaYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 15, 2015
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory LymphomasYago Nieto, Benigno C Valdez, Peter F Thall, et al.
Blood|July 22, 2016
IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantationAnushruti Sarvaria, Rafet Basar, Rohtesh S Mehta, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 31, 2013
The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantationRohtesh S Mehta, Antonio Di Stasi, Borje S Andersson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 6, 2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic SyndromeGheath Alatrash, Peter F Thall, Benigno C Valdez, et al.
American Journal of Hematology|January 11, 2012
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myelomaQaiser Bashir, Hassan Khan, Robert Z Orlowski, et al.
Transplantation and Cellular Therapy|March 30, 2021
Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple MyelomaSamer A Srour, Rima M Saliba, Qaiser Bashir, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 28, 2016
Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe PancytopeniaFleur M Aung, Benjamin Lichtiger, Gabriela Rondon, et al.
Annals of Hematology|June 28, 2019
Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemiaNeeraj Y Saini, Romil D Patel, Ankur Varma, et al.
Blood|April 16, 2008
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximabIssa F Khouri, Peter McLaughlin, Rima M Saliba, et al.
Pageof 24